STOCK TITAN

Cardiff Oncology Inc - CRDF STOCK NEWS

Welcome to our dedicated news page for Cardiff Oncology (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cardiff Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cardiff Oncology's position in the market.

Rhea-AI Summary
Cardiff Oncology announced positive clinical and preclinical data for their lead program in RAS-mutated metastatic colorectal cancer (mCRC). They also expanded their relationship with Pfizer for a new Phase 2 trial. Onvansertib monotherapy showed activity in refractory patients with small cell lung cancer. The company has approximately $81.4 million in cash and expects to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary
Cardiff Oncology plans to release financial results for the third quarter on November 2 and will hold a conference call and webcast on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences earnings
-
Rhea-AI Summary
Cardiff Oncology announces positive clinical data with onvansertib in pancreatic cancer and small cell lung cancer, plans for a first-line trial in pancreatic cancer, and ongoing enrollment in small cell lung cancer trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
Rhea-AI Summary
Cardiff Oncology, Inc. (Nasdaq: CRDF) will present at the Baird Global Healthcare Conference on September 12, 2023, and the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. The presentations will be given by Mark Erlander, CEO. Interested parties can register for the live webcast of the H.C. Wainwright conference on the Cardiff Oncology website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
conferences
-
Rhea-AI Summary
Cardiff Oncology announces new lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship. Interim topline data expected in mid-2024. Company has approximately $89.4 million in cash and projected runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.38%
Tags
-
Rhea-AI Summary
Cardiff Oncology plans to advance its lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct a new CRDF-004 trial with support from Pfizer Ignite. The company estimates 48,000 new patients annually in the first-line RAS-mutated mCRC setting. Cash position on June 30, 2023, was $89.4 million, sufficient to fund operations into 2025. Interim topline results from the CRDF-004 trial are expected in mid-2024. Cardiff Oncology will discontinue enrollment in its ONSEMBLE second-line trial to focus on the first-line program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.85%
Tags
none
Rhea-AI Summary
Cardiff Oncology grants non-qualified stock options to a new employee. The options allow the purchase of 50,016 shares of common stock at an exercise price of $1.49 per share. Vesting occurs over a 4-year period, with 25% of the shares vesting after 1 year and the remaining shares vesting monthly over the following 36 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
Cardiff Oncology Inc

Nasdaq:CRDF

CRDF Rankings

CRDF Stock Data

250.64M
41.29M
7.56%
15.16%
7.63%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About CRDF

trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh